Urmăriți
M. Frank Erasmus
M. Frank Erasmus
Specifica, Inc.
Adresă de e-mail confirmată pe specifica.bio
Titlu
Citat de
Citat de
Anul
Many routes to an antibody heavy-chain CDR3: necessary, yet insufficient, for specific binding
S D’Angelo, F Ferrara, L Naranjo, MF Erasmus, P Hraber, ARM Bradbury
Frontiers in immunology 9, 395, 2018
1122018
Drug-like antibodies with high affinity, diversity and developability directly from next-generation antibody libraries
AAR Teixeira, MF Erasmus, S D’Angelo, L Naranjo, F Ferrara, ...
MAbs 13 (1), 1980942, 2021
402021
A pandemic-enabled comparison of discovery platforms demonstrates a naïve antibody library can match the best immune-sourced antibodies
F Ferrara, MF Erasmus, S D’Angelo, C Leal-Lopes, AA Teixeira, ...
Nature communications 13 (1), 462, 2022
372022
A single donor is sufficient to produce a highly functional in vitro antibody library
MF Erasmus, S D’Angelo, F Ferrara, L Naranjo, AA Teixeira, R Buonpane, ...
Communications Biology 4 (1), 350, 2021
302021
Allergen valency, dose, and FcεRI occupancy set thresholds for secretory responses to Pen a 1 and motivate design of hypoallergens
A Mahajan, LA Youssef, C Cleyrat, R Grattan, SR Lucero, CP Mattison, ...
The Journal of Immunology 198 (3), 1034-1046, 2017
182017
Simultaneous affinity maturation and developability enhancement using natural liability-free CDRs
AAR Teixeira, S D’Angelo, MF Erasmus, C Leal-Lopes, F Ferrara, ...
MAbs 14 (1), 2115200, 2022
172022
Dynamic pre-BCR homodimers fine-tune autonomous survival signals in B cell precursor acute lymphoblastic leukemia
MF Erasmus, K Matlawska-Wasowska, I Kinjyo, A Mahajan, SS Winter, ...
Science signaling 9 (456), ra116-ra116, 2016
172016
Recombinant Antibodies against Mycolactone
N Naranjo, F Ferrara, N Blanchard, C Demangel, S D’Angelo, ...
Toxins 11 (346), 2019
122019
Insights into next generation sequencing guided antibody selection strategies
MF Erasmus, F Ferrara, S D’Angelo, L Spector, C Leal-Lopes, AA Teixeira, ...
Scientific reports 13 (1), 18370, 2023
112023
Exploiting next-generation sequencing in antibody selections–a simple PCR method to recover binders
F Ferrara, AA Teixeira, L Naranjo, MF Erasmus, S D’Angelo, ...
MAbs 12 (1), 1701792, 2020
92020
Rapid purification of billions of circulating CD19+ B cells directly from leukophoresis samples
F Ferrara, M Kolnik, S D’Angelo, FM Erasmus, D Vorholt, ARM Bradbury
New Biotechnology 46, 14-21, 2018
72018
Determining the affinities of high-affinity antibodies using KinExA and surface plasmon resonance
MF Erasmus, M Dovner, F Ferrara, S D’Angelo, AA Teixeira, C Leal-Lopes, ...
MAbs 15 (1), 2291209, 2023
52023
Spatial stochastic model of the Pre-B cell receptor
R Kerketta, MF Erasmus, BS Wilson, ÁM Halász, JS Edwards
IEEE/ACM transactions on computational biology and bioinformatics 20 (1 …, 2022
32022
Many routes to an antibody heavy-chain CDR3: necessary, yet insufficient, for specific binding. Front Immunol. 2018; 9: 395
S D'Angelo, F Ferrara, L Naranjo, MF Erasmus, P Hraber, ARM Bradbury
22018
AIntibody: an experimentally validated in silico antibody discovery design challenge
MF Erasmus, L Spector, F Ferrara, R DiNiro, TJ Pohl, K Perea-Schmittle, ...
Nature Biotechnology, 1-6, 2024
12024
Pandemic’s silver lining
F Ferrara, S D’Angelo, MF Erasmus, AA Teixeira, C Leal-Lopes, ...
MAbs 14 (1), 2133666, 2022
12022
Characterization of the metal binding by the anti-sphingosine-1-phosphate antibody LT1002
MF Erasmus
Sciences, 2012
12012
A next-generation Fab library platform directly yielding drug-like antibodies with high affinity, diversity, and developability
F Ferrara, A Fanni, AAR Teixeira, E Molina, C Leal-Lopes, A DeAguero, ...
Mabs 16 (1), 2394230, 2024
2024
ANTIBODY LIBRARIES WITH MAXIMIZED ANTIBODY DEVELOPABILITY CHARACTERISTICS
ARM Bradbury, MF Erasmus, A Teixeira
US Patent App. 18/592,499, 2024
2024
ANTIBODY LIBRARIES WITH MAXIMIZED ANTIBODY DEVELOPABILITY CHARACTERISTICS
ARM Bradbury, MF Erasmus, A Teixeira
US Patent App. 18/592,484, 2024
2024
Sistemul nu poate realiza operația în acest moment. Încercați din nou mai târziu.
Articole 1–20